NCT01088893

Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy

A Randomized Study of mTOR Inhibition by RAD001 (Everolimus) in Invasive Breast Cancer Patients After Pre-operative Use of Anthracycline and/or Taxane-based Chemotherapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Organisation for Oncology and Translational Research · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized controlled pilot study investigating signals involved in drug resistance to chemotherapy. Patient will be randomized to undergo observation or to receive Everolimus after completion of neoadjvuant treatment (anthracycline and/or taxane-based) and before surgery. The patients will be monitored for efficacy and safety.

Conditions

• Breast Neoplasms

Interventions

Type	Name	Description
DRUG	Everolimus	10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery

Timeline

• Start date: 2009-11-01
• Primary completion: 2012-12-01
• Completion: 2013-03-01
• First posted: 2010-03-17
• Last updated: 2012-05-24

Locations

1 site across 1 country: China